Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

April 16, 2024

https://www.globenewswire.com/news-release/2024/04/16/2863530/0/en/Acumen-Pharmaceuticals-Presents-First-Comprehensive-Clinical-and-Biomarker-Data-for-Sabirnetug-ACU193-at-American-Academy-of-Neurology-2024-Annual-Meeting.html

CHARLOTTESVILLE, Va., April 16, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present the comprehensive clinical and biomarker results from its positive Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) in early AD during an Emerging Science Session at the American Academy of Neurology (AAN) 2024 Annual Meeting in Denver on April 16, 2024. The results build upon Acumen’s prior presentations at the AD/PD™ 2024 Annual Meeting and positive topline data first announced in July 2023 and will be presented together for the first time with expanded analysis.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.